SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage

Cells. 2023 Nov 17;12(22):2644. doi: 10.3390/cells12222644.

Abstract

Cells respond to DNA damage by activating a complex array of signaling networks, which include the AMPK and mTOR pathways. After DNA double-strand breakage, ATM, a core component of the DNA repair system, activates the AMPK-TSC2 pathway, leading to the inhibition of the mTOR cascade. Recently, we showed that both AMPK and mTOR interact with SMYD3, a methyltransferase involved in DNA damage response. In this study, through extensive molecular characterization of gastrointestinal and breast cancer cells, we found that SMYD3 is part of a multiprotein complex that is involved in DNA damage response and also comprises AMPK and mTOR. In particular, upon exposure to the double-strand break-inducing agent neocarzinostatin, SMYD3 pharmacological inhibition suppressed AMPK cascade activation and thereby promoted the mTOR pathway, which reveals the central role played by SMYD3 in the modulation of AMPK-mTOR signaling balance during cancer cell response to DNA double-strand breaks. Moreover, we found that SMYD3 can methylate AMPK at the evolutionarily conserved residues Lys411 and Lys424. Overall, our data revealed that SMYD3 can act as a bridge between the AMPK and mTOR pathways upon neocarzinostatin-induced DNA damage in gastrointestinal and breast cancer cells.

Keywords: AMPK; DNA damage; SMYD3; breast cancer; gastrointestinal cancer; mTOR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Breast Neoplasms*
  • DNA
  • DNA Damage
  • Female
  • Histone-Lysine N-Methyltransferase / genetics
  • Humans
  • TOR Serine-Threonine Kinases / metabolism
  • Zinostatin*

Substances

  • AMP-Activated Protein Kinases
  • Zinostatin
  • TOR Serine-Threonine Kinases
  • DNA
  • SMYD3 protein, human
  • Histone-Lysine N-Methyltransferase